Administration of Ixazomib

Ixazomib is indicated for the treatment of multiple myeloma. Its mechanism of action involves blocking a protein that promotes the growth and proliferation of cancer cells, thereby slowing down or inhibiting the spread of cancer cells.

Administration of Ixazomib

Ixazomib is available as oral capsules, with strengths of 2.3 mg, 3 mg, and 4 mg.

Adult Dosage

The recommended dose is 4 mg per administration. According to the drug's approved clinical studies, the medication should be taken once weekly on Days 1, 8, and 15 of a 28 - day treatment cycle.

It should be noted that ixazomib is usually administered in combination with dexamethasone and lenalidomide, following a specific dosing schedule within each cycle. Both ixazomib and dexamethasone are given on Days 1, 8, and 15 of the cycle; however, the administration times of the two drugs must be staggered. This is because ixazomib should be taken on an empty stomach, while dexamethasone needs to be taken with food.

Ixazomib should be taken with a full glass of water either 2 hours after a meal or 1 hour before a meal. The drug should be administered at the same fixed day and time every week. If a dose is missed, a make - up dose can be taken only if at least 72 hours remain before the next scheduled dose.

Nausea and Vomiting Induced by Ixazomib

In the drug's approved clinical studies, these reactions mainly occurred at the initial stage of treatment (within the first three months of the first cycle). Antiemetics were added to the treatment regimen in some cases, and some patients also received prophylactic antiemetic therapy.

The incidence of the first episode of diarrhea was also the highest in the first three months of treatment and then gradually decreased. Some patients were treated with antidiarrheals, among which loperamide was the most commonly used. For the constipation that occurred in a small number of patients, it cannot be ruled out that it may be caused by the use of opioid drugs for bone pain.

The skin rash that occurs after the use of ixazomib usually presents as erythematous, maculopapular lesions, or generalized rash. Similar to nausea and diarrhea, the incidence of rash is the highest in the first three months of treatment and can be controlled by antihistamines, steroids, or dose reduction.

Administration Instructions for Ixazomib

1. Ixazomib is available as oral capsules, with strengths of 2.3 mg, 3 mg, and 4 mg. It is for oral administration.

2. The recommended dose is 4 mg per administration. According to the drug's approved clinical studies, the medication should be taken once weekly on Days 1, 8, and 15 of a 28 - day treatment cycle.

3. It is also important to remember that ixazomib should be administered in combination with dexamethasone and lenalidomide, following a specific dosing schedule within each cycle. Both ixazomib and dexamethasone are given on Days 1, 8, and 15 of the cycle; special attention must be paid to separate their administration times, because ixazomib should not be taken with food, while dexamethasone should be taken with food.

4. Ixazomib should be taken with a full glass of water at least 2 hours after a meal or at least 1 hour before a meal. The drug should be taken on the same day and at the same time each week. If a dose is missed, a make - up dose can be taken only if at least 72 hours remain before the next scheduled dose.